The estimated Net Worth of Jay Parrish is at least $127 Thousand dollars as of 1 April 2021. Jay Parrish owns over 6,944 units of Vir Biotechnology Inc stock worth over $126,877 and over the last 4 years he sold VIR stock worth over $0. In addition, he makes $0 as Chief Business Officer at Vir Biotechnology Inc.
Jay has made over 11 trades of the Vir Biotechnology Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he exercised 6,944 units of VIR stock worth $10,555 on 1 April 2021.
The largest trade he's ever made was exercising 75,000 units of Vir Biotechnology Inc stock on 1 July 2020 worth over $115,500. On average, Jay trades about 25,884 units every 29 days since 2020. As of 1 April 2021 he still owns at least 16,204 units of Vir Biotechnology Inc stock.
You can see the complete history of Jay Parrish stock trades at the bottom of the page.
Dr. Jay Parrish Ph.D. serves as Chief Business Officer of the Company. Prior to that, Dr. Parrish served as our Senior Vice President, Strategy and Corporate Development, from April 2017 to July 2017. Dr. Parrish is a Venture Partner at ARCH Venture Partners, L.P., or ARCH Venture Partners, where he has served since May 2016. From September 2011 to May 2016, Dr. Parrish served in Gilead’s Corporate Development group, where he was involved in building Gilead’s oncology and infectious disease portfolio, ultimately leading infectious disease business development for the company. Dr. Parrish also served as a scientist in Gilead’s medicinal chemistry group, from March 2004 to September 2011. Since 2012, Dr. Parrish has served as a part-time instructor at UC Berkeley Extension, where he teaches chemistry to undergraduates and post-baccalaureates. He also previously completed a postdoctoral fellowship at the Scripps Research Institute. Dr. Parrish received his B.S. in Chemistry from Emory University, a Ph.D. in Synthetic Organic Chemistry from the University of South Florida and an M.B.A. from the University of California, Berkeley Haas School of Business.
Jay Parrish is 45, he's been the Chief Business Officer of Vir Biotechnology Inc since 2017. There are 20 older and 2 younger executives at Vir Biotechnology Inc. The oldest executive at Vir Biotechnology Inc is Phillip Sharp, 75, who is the Independent Director.
Jay's mailing address filed with the SEC is C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO, CA, 94158.
Over the last 5 years, insiders at Vir Biotechnology Inc have traded over $197,171,926 worth of Vir Biotechnology Inc stock and bought 6,960,011 units worth $139,246,875 . The most active insiders traders include Norbert W Bischofberger, Endurance (Cayman) Ltd Sb I..., and Kristina Burow. On average, Vir Biotechnology Inc executives and independent directors trade stock every 7 days with the average trade being worth of $478,115. The most recent stock trade was executed by Janet Napolitano on 9 September 2024, trading 12,190 units of VIR stock currently worth $95,082.
vir brings together cutting-edge innovations with leading scientific expertise and management to take on some of the world’s most challenging infectious diseases for which solutions are non-existent or inadequate. vir seeks to take a new approach, using breakthroughs in immune programming to manipulate pathogen-host interactions. the company will take a multi-program, multi-platform approach to applying these breakthroughs, guided by rigorous science and driven by medical need.
Vir Biotechnology Inc executives and other stock owners filed with the SEC include: